AU2003227919A1 - Dopamine receptor modulators as antipsychotic agents - Google Patents
Dopamine receptor modulators as antipsychotic agentsInfo
- Publication number
- AU2003227919A1 AU2003227919A1 AU2003227919A AU2003227919A AU2003227919A1 AU 2003227919 A1 AU2003227919 A1 AU 2003227919A1 AU 2003227919 A AU2003227919 A AU 2003227919A AU 2003227919 A AU2003227919 A AU 2003227919A AU 2003227919 A1 AU2003227919 A1 AU 2003227919A1
- Authority
- AU
- Australia
- Prior art keywords
- receptor modulators
- dopamine receptor
- antipsychotic agents
- antipsychotic
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000015554 Dopamine receptor Human genes 0.000 title 1
- 108050004812 Dopamine receptor Proteins 0.000 title 1
- 239000000164 antipsychotic agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0210762.1 | 2002-05-10 | ||
| GBGB0210762.1A GB0210762D0 (en) | 2002-05-10 | 2002-05-10 | Compounds |
| PCT/GB2003/001983 WO2003095428A1 (en) | 2002-05-10 | 2003-05-09 | Dopamine receptor modulators as antipsychotic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003227919A1 true AU2003227919A1 (en) | 2003-11-11 |
Family
ID=9936447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003227919A Abandoned AU2003227919A1 (en) | 2002-05-10 | 2003-05-09 | Dopamine receptor modulators as antipsychotic agents |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070043026A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1503989A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005532318A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003227919A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0210762D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003095428A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY133587A (en) | 2002-05-29 | 2007-11-30 | Glaxo Group Ltd | Aromatic sulfones and their medical use |
| GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| US20050137186A1 (en) * | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| US8207160B2 (en) | 2003-12-18 | 2012-06-26 | Abbott Gmbh & Co. Kg | Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor |
| TW200611701A (en) * | 2004-06-18 | 2006-04-16 | Glaxo Group Ltd | Novel compounds |
| EP2371814A1 (en) * | 2004-10-14 | 2011-10-05 | Abbott GmbH & Co. KG | Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| EP1837332A1 (en) * | 2006-03-23 | 2007-09-26 | Laboratorios Del Dr. Esteve, S.A. | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments |
| US7897595B2 (en) | 2006-05-26 | 2011-03-01 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| US8258134B2 (en) * | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321254A (en) * | 1980-09-26 | 1982-03-23 | Smithkline Corporation | Antiallergic imidodisulfamides |
| US5112824A (en) * | 1989-12-08 | 1992-05-12 | Merck & Co., Inc. | Benzofuran compounds as class III antiarrhythmic agents |
| US5684195A (en) * | 1994-07-14 | 1997-11-04 | G. D. Searle & Co. | Method of preparing sulfmonamides from sulfones |
| NZ332757A (en) * | 1996-06-17 | 1999-06-29 | Smithkline Beecham Plc | Substituted tetrahydroisoquinoline benzamide derivatives and their use as anticonvulsants and psycho-active agents |
| IL131756A0 (en) * | 1997-03-18 | 2001-03-19 | Smithkline Beecham Plc | Substituted isoquinoline derivatives and their use as anticonvulsants |
| JP2001521026A (ja) * | 1997-10-24 | 2001-11-06 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 置換イソキノリン誘導体および抗痙攣薬としての使用 |
| DE10053799A1 (de) * | 2000-10-30 | 2002-05-08 | Bayer Ag | Verwendung von Tetrahydroisochinolinsulfonamiden |
-
2002
- 2002-05-10 GB GBGB0210762.1A patent/GB0210762D0/en not_active Ceased
-
2003
- 2003-05-09 AU AU2003227919A patent/AU2003227919A1/en not_active Abandoned
- 2003-05-09 JP JP2004503446A patent/JP2005532318A/ja active Pending
- 2003-05-09 EP EP03725384A patent/EP1503989A1/en not_active Withdrawn
- 2003-05-09 US US10/513,919 patent/US20070043026A1/en not_active Abandoned
- 2003-05-09 WO PCT/GB2003/001983 patent/WO2003095428A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005532318A (ja) | 2005-10-27 |
| WO2003095428A1 (en) | 2003-11-20 |
| US20070043026A1 (en) | 2007-02-22 |
| EP1503989A1 (en) | 2005-02-09 |
| GB0210762D0 (en) | 2002-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003253535A1 (en) | N-4-piperidinyl compounds as ccr5 modulators | |
| AU2003290700A1 (en) | Farnesoid x receptor agonists | |
| EP1569685B8 (en) | Complement receptor 2 targeted complement modulators | |
| AU2003241836A1 (en) | Lpa receptor antagonists | |
| AU2003212708A1 (en) | Baculovirus expression system | |
| AU2003259482A1 (en) | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators | |
| AU2003277576A1 (en) | Receptor function controlling agent | |
| ZA200604778B (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| IL164261A0 (en) | Tropane derivatives as ccr5 modulators | |
| AU2003266267A1 (en) | Birefringent marking | |
| AU2003275838A1 (en) | Pyrrolidin-2-on derivatives as ep4 receptor agonists | |
| AU2003219814A1 (en) | Release agents | |
| AU2003256922A1 (en) | Substituted heterocyclic compounds as modulators of the ccr5 receptor | |
| PL371344A1 (en) | Benzenesulfonamide derivatives as antipsychotic agents | |
| AU2002335075A1 (en) | Estrogen receptor modulators | |
| AU2003301299A1 (en) | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators | |
| AU2003248356A1 (en) | Beta3-adrenergic receptor agonists | |
| AU2002347552A1 (en) | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | |
| AU2003231523A1 (en) | Estrogen receptor modulators | |
| AU2003293495A1 (en) | 2-aryl thiazole derivatives as kcnq modulators | |
| AU2003251627A1 (en) | Carvedilol hydrobromide | |
| AU2003274836A1 (en) | Compensation device | |
| AU2003227449A1 (en) | Demultiplexing device | |
| AU2003244148A1 (en) | Antifungal agents for external use | |
| AU2003302405A1 (en) | T-cell receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase | ||
| TH | Corrigenda |
Free format text: IN VOL 18, NO 2, PAGE(S) 542 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAMES FORBES, I.; LIGHTFOOT, A.; PAYNE, A.; GLAXO GROUP LIMITE; GRIBBLE, A. AND COOPER, D., APPLICATION NO. 2003227919, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 24.11.2003 |